Results On the WG intervention, WG consumption reached 168 g/day (P < 0.001), accompanied by an increase in plasma ARs (P < 0.001) and fibre intake (P < 0.001), without affecting other aspects of dietary intake. On the WG arm, there were trends for lower ex vivo activation of CD4 + T cells and circulating concentrations of IL-10, C-reactive protein, C-peptide, insulin and plasminogen activator inhibitor-1. The percentage of CD4 + central memory T cells and circulating levels of adipsin tended to increase during the WG intervention. Conclusions Despite the dramatic increase in WG consumption, there were no effects on phenotypic or functional immune parameters, markers of inflammation or metabolic markers. 
Introduction
Subclinical inflammation is associated with cardiovascular diseases (CVDs) [1] , metabolic syndrome and type 2 diabetes [2, 3] . Circulating concentrations of inflammatory markers, such as tumour necrosis factor (TNF)-α, IL-6, IL-10 and C-reactive protein (CRP) are elevated in obese individuals and decrease with weight loss [4, 5] and may directly contribute to vascular injury, insulin resistance and atherogenesis [6] .
Wholegrain (WG) foods have been suggested to reduce the risk of CVD [7, 8] , metabolic syndrome [8] and type 2 diabetes [7, 8] . However, the effects of WG consumption on health are still poorly understood. Some epidemiological studies have demonstrated an inverse association between WG consumption and CRP in non-diabetic [7, 9] and diabetic [10] individuals, and between WG intake and elevated fasting levels of glucose [7] , insulin [7, 11, 12] , C-peptide [11] and leptin [11] , but not all studies are consistent [11] . Intervention studies also present mixed data regarding effects of WG on CRP and other inflammatory markers. Some WG interventions (4-12 weeks) report reductions in IL-6 [13] and CRP [14] , especially in overweight and diabetic individuals or subjects with metabolic syndrome, while others report no effect of WG consumption ranging between 48 and 120 g/day on CRP, IL-6, PAI-1 [15] [16] [17] , insulin [15, 16, 18, 19] or glucagon [18] . Interestingly, WG intakes were similar or higher [15, 16] in the studies that reported no effects compared to those reporting positive effects, but it is notable that studies conducted in healthy volunteers tend to report no effect [15] [16] [17] [18] , whereas those conducted in non-healthy subjects tend to report positive effects [14, 20, 21] . This may be at least partly due to interventions in healthy subjects achieving a relatively modest level of WG intake (56-120 g/day in previous studies compared with an average intake of 168 g/day in the current study). Some of these studies added WG to the diet rather than replacing refined grain products with WG products, or simply provided advice, whereas the current study specifically replaced RG products with WG products to achieve a high intake of WG compared with virtually no intake of WG during the RG period.
Currently, limited data are available on the impact of increased WG consumption on immune function. However, WGs are important sources of phytic acid [22] , which may enhance the activity of natural killer (NK) cells [23, 24] . WGs also contain fructans, which have a degree of polymerisation between that of fructooligosaccharides and inulin [25] and may modulate immune function [26, 27] . The objective of this randomized 6-week cross-over study was therefore to assess the effect of increasing WG consumption to at least 80 g/day on markers of systemic inflammation and glucose metabolism and on phenotypic and functional aspects of the immune system in healthy, middle-aged adults, who had a habitual diet low in WG. The study was conducted in healthy individuals with a wide range of BMI in an effort to capture a population of likely consumers who span a wide range of body composition, but avoiding complications associated with diagnosed disease. While previous studies have focused on effects of WG on blood lipids, the current study examined immune and inflammatory markers, for which the issue of healthy versus non-healthy subjects has not yet been considered with respect to WGs.
Methods

Subjects
Thirty-three healthy subjects (twelve male, twenty-one female), 40-65 years of age, with habitual WG consumption of <1½ serving or 24 g/day and BMI 20-35 kg/m 2 were recruited into the study. Exclusion criteria included diagnosed diabetes, heart disease, stroke, vascular disease, inflammatory disease, renal, bowel, liver or pancreatic disease, medication for hyperlipidaemia, hypertension, hypercoagulation, inflammatory conditions or depression, prescribed aspirin, asthma, allergies, smoking, excessive consumption of alcohol (>21 units/week for men, >15 units/week for women), planned influenza vaccination or vaccination during the previous 12 months, consumption of prebiotics or probiotics or antibiotic treatment during the previous 3 months. Baseline characteristics of the subjects are shown in Table 1 . This study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving human subjects were approved by the University of Reading Research and Ethics Committee. Written informed consent was obtained from all subjects. The trial was registered (ISRCTN36521837).
Recruitment
Potential subjects responding to advertisements were sent a participant information sheet and those who were interested in participating completed a medical and lifestyle questionnaire either online or by telephone. Subjects consuming <24 g/day of WG were identified using a FFQ, which was modified from Ross et al. [28] for use in the UK (48 items, 8 frequencies, with specified portion sizes for breakfast cereals, pasta and rice). Suitable subjects were then invited to the Hugh Sinclair Unit of Human Nutrition (Department of Food and Nutritional Sciences, University of Reading, UK) for a screening visit, where height, weight, waist circumference and blood pressure were measured and a blood sample for a full blood count was taken.
Study design
During a 2-week run-in period, dietary assessment was conducted using 3-day food diaries (3DFDs) for any three consecutive days, which were also used to provide specific, tailored advice to achieve the WG target intakes. In consultation with a dietician, subjects were advised to consume a diet high in WG (>80 g/day) or low in WG (<16 g/day, RG diet) in a cross-over study, with intervention periods lasting 6 week each, separated by a 4-week washout (Fig. 1 ). Subjects were randomized based on age, gender and BMI by a research assistant, who was not involved in the analysis, using covariate adaptive randomization software. Commercially available pasta, rice, snacks and breakfast cereals in both the WG and RG categories [29] were provided to The intakes were calculated by a dietician on an individual basis for every food included in the dietary records, using any available information relating to WG content of foods, or, in some cases, by contacting manufacturers. They were also calculated (much more simply) by the diet compliance diaries, which recorded consumption of the foods that were provided as part of the study. Data calculated using both methods allow comparison. This emphasises the fact that during the WG intervention, almost all of the WG intake came from the products provided to the subjects, with very little being contributed by other products. This is perhaps not surprising, since the subjects were preselected to be very low habitual consumers of WG. While on the study, subjects were asked not to consume products containing prebiotics or probiotics. During each of the two intervention periods, subjects completed a 3DFD. All 3DFD were analysed using Dietplan6 (Forestfield Software Ltd.). Fasting blood and saliva samples were collected at the beginning and end of each of the intervention periods. Available data on which to perform power calculations were limited, so the sample size was based on data derived from interventions investigating the effect of prebiotics on phenotypic and functional immune parameters and the effect of prebiotics and WGs on the gut microbiota. A sample size of 33 subjects per group was sufficient to detect an 8 % difference in NK cell activity, with a two-tailed significance level of 5 % and a power of 80 %.
Saliva, plasma and serum samples Saliva was collected by spitting into Eppendorf tubes, centrifuged at 13,000×g for 10 min at 4 °C, and the supernatants stored at −20 °C for <15 months before further analysis. Plasma was prepared from blood collected in EDTA tubes by centrifugation at 2,000×g for 15 min at room temperature (RT), and serum was prepared from blood collected in serum sep clot activator tubes by centrifugation at 1,800×g for 10 min at RT. Samples were frozen at −20 °C within 1 h from collection until further analysis.
Preparation of peripheral blood mononuclear cells (PBMCs)
Heparinised whole blood (15 mL) was layered onto Lympholyte-H (25 mL; Cedarlane laboratories, Texas, USA), before centrifuging the samples at 550×g for 15 min at RT and collecting the PBMC-rich interface. PBMCs were washed in PBS (Oxoid, Hampshire, UK), resuspended in 2.5 mL of RPMI 1640 and layered onto 2.5 mL Lympholyte-H. Samples were then centrifuged once more at 550×g for 15 min at RT, before collecting the PBMC-rich interface and washing with PBS. PBMCs were resuspended in complete medium (RPMI 1640 with HEPES and l-glutamine medium containing 100 U/mL penicillin and 0.1 mg/mL streptomycin), counted in a Z1™ series Coulter Counter ® (Beckman Coulter, High Wycombe, UK) and adjusted to 5 × 10 6 cells/mL.
Analysis of plasma alkylresorcinols (ARs)
To assess compliance, plasma ARs were analysed by extraction with diethyl ether and normal phase liquid chromatography/tandem mass spectrometry (LC-MS/ MS) after extraction with diethyl ester [30] modified to a 100 mm × 2 mm column and a run time of 8 min. Matrix matched calibration was used, and two control samples were run in triplicate with each batch. Control samples and calibration curve standards were run in random order throughout each sequence. Intra-batch repeatability for each control plasma sample was <10 % and inter-batch repeatability <15 %.
White blood cell (WBC) counts 
Naïve and memory T lymphocyte subsets
Whole blood in EDTA tubes was stained with a mixture of APC-Cy7 mouse anti-human CD3, FITC mouse anti-human CD4, PerCP-Cy5.5 mouse anti-human CD8, PE-Cy7 mouse anti-human CD45RA and PE rat antihuman CD197 (CCR7) (BD Biosciences, Oxford, UK) in the dark for 45 min at RT. Erythrocytes were lysed using BD Pharm Lyse™ lysing buffer (BD Biosciences, Oxford, UK), incubating in the dark for 20 min at RT, before washing twice with BD CellWASH™ (BD Biosciences). Samples were analysed on a BD FACSCanto II flow cytometer. Results are reported as percentages of parent CD8 + and CD4
+ T lymphocyte subsets.
Ex vivo phagocytosis monocytes and granulocytes
Monocyte and granulocyte phagocytosis was assessed using the PHAGOTEST ® kit (Glycotype Biotechnology, Heidelberg, Germany); both the percentage of monocytes and granulocytes engaged in phagocytosis of opsonised FITC-labelled Escherichia coli bacteria and mean fluorescence intensity (MFI), reflecting degree of phagocytosis, were recorded. Samples were analysed on a BD FACSCanto II flow cytometer within 60 min.
Ex vivo T cell activation
Heparinised whole blood was diluted 1:10 with complete medium, stimulated with concanavalin A (Sigma-Aldrich, Poole, UK) or CytoStim (Miltenyi Biotec, Surrey, UK) at final concentrations of 25 and 0.1 µl/mL, respectively, and incubated at 37 °C, 5 % CO 2 for 4 h. Samples were washed once with EDTA buffer (2 mM EDTA in PBS, containing 0.5 % v/v BSA stain buffer) before staining with a mixture of APC-Cy7 mouse anti-human CD3, FITC mouse antihuman CD4, PE mouse anti-human CD8 and APC mouse anti-human CD69 (BD Biosciences, Oxford, UK) in the dark for 45 min at RT. Erythrocytes were lysed using BD Pharm Lyse™ lysing buffer, incubating in the dark for 20 min at RT, before washing twice with BD CellWASH™. Finally, 7-AAD (BD Biosciences, Oxford, UK) was added as a viability stain and samples were analysed on a BD FACSCanto II flow cytometer.
NK cell activity assay K562 cells were stained with 0.2 % trypan blue (SigmaAldrich, Poole, UK) and counted using a haemocytometer before removing 5 × 10 6 live K562 cells from the suspension. Cells were washed twice in PBS and stained with carboxyfluorescein diacetate succinimidyl ester (CFDA-SE, 100 μg/mL, Sigma-Aldrich) in dimethyl sulphoxide (Sigma-Aldrich) at 37 °C, 5 % CO 2 for 45 min, during which CFDA-SE was intracellularly converted to carboxyfluorescein succinimidyl ester (CFSE). CFSE-labelled K562 cells were washed twice in PBS, re-suspended and diluted 1:100 in complete medium. PBMCs were then incubated together with the K562 cells at ratios of 100:1, 50:1, 25:1, 12.5:1 and 0:1 (PBMC/K562) at 37 °C, 5 % CO 2 for 2 h. Propidium iodide (1 mg/mL, Sigma-Aldrich) in PBS was used to stain dead K562 cells, prior to flow-cytometric analysis in a FACSCanto II (BD Biosciences).
Serum cytokine analysis
Serum concentrations of IL-1β, IL-6, IL-8, IL-10 and TNF-α were analysed by Luminex ® 100™ (Luminex Corporation), using a high-sensitivity multiplex cytokine kit (R&D Systems, Abingdon, UK), according to the manufacturer's instructions. Standard curves were generated by the Luminex ® software (mean R 2 = 0.9991). All samples for individual subjects were analysed within a single plate and the intra-assay CV for the Luminex platform was 5.9 %.
CRP analysis CRP concentrations were analysed by an Automatic Analyzer ILab 600 using enzyme-based kits and appropriate quality controls (Instrumentation Laboratory Ltd.). All samples for individual subjects were analysed within a single batch, and the intra-assay CV was 1.6 %.
Salivary secretory IgA (sIgA) Salivary sIgA was analysed using Immunodiagnostic sIgA ELISA kit (Oxford Biosystems, Oxford, UK), in accordance with the manufacturer's instructions. All samples for individual subjects were analysed within a single plate and the intra-assay CV was 9.0 %.
Metabolic and inflammatory markers
Serum concentrations of C-Peptide, ghrelin, gastric inhibitory polypeptide (GIP), glucagon-like peptide-1 (GLP-1), glucagon, insulin, leptin, PAI-1, resistin, visfatin, adiponectin and adipsin were analysed by Luminex ® 100™, using the Bio-Plex Pro Human Diabetes 10-Plex Assay and BioPlex Pro Human Diabetes Adipsin and Adiponectin Assays (Bio-Rad Laboratories) according to the manufacturer's instructions. All samples for individual subjects were analysed within a single plate and the intra-assay CV was 16.6 %.
Statistical analysis
Analysis of the data acquired by flow cytometry was performed by BD FACSDiva Software (BD Biosciences) and statistical analysis was carried out on MINITAB, version 15 (MINITAB Ltd. State College, PA, USA). Data are means and SD or SEM at baseline and end of intervention (within each arm), as well as difference from the within-arm baseline (Δ intervention) for both interventions. Data were normally distributed, as confirmed by the Kolmogorov-Smirnov normality test. To assess whether the order of the intervention arms had an effect on the data, baseline means were compared using two-sample T tests and no statistical differences were found. With the exceptions mentioned below, a general linear model (GLM) was used to analyse the data, in which Δ intervention and gender were specified as fixed-model parameters and starting diet as a random parameter, while age and baseline measurements of BMI, systolic and diastolic blood pressure, body fat percentage, waist circumference, alcohol consumption, plasma ARs, habitual fibre and WG consumption, CRP and blood biochemistry (i.e. total cholesterol, triglycerides, LDL and HDL cholesterol and glucose) were listed as covariates. The analysis of 3DFD and ARs was performed using a single factor GLM and further comparisons made using Tukey simultaneous tests. Spearman's ρ correlation coefficients between studied parameters and ARs, fibre intake and WG intake were calculated and P values reported. In all cases, the level of significance was set at 5 and 10 % for effects and trends respectively.
Results
Dietary analysis, assessment of WG intake and plasma ARs A habitual diet low in WG intake was a prerequisite for subjects taking part in this study and two methods were used to assess it: the FFQ at screening and the 3DFD during the run-in period. Subjects were recruited on the basis of the FFQ, although comparison with the 3DFD suggests that the FFQ slightly, but significantly, underestimated habitual consumption of WG (P < 0.001) (data not shown). Using data from the 3DFD administered during the run-in period, recruited subjects consumed on average 28 g/day of WG, which was slightly higher than the threshold of 24 g/ day. Nevertheless, the substitution of habitual grain-based foods with the provided WG varieties during the WG intervention period resulted in consumption of WG far exceeding the target of 80 g/day and reaching an average of 168 g/ day, with a range of 67-335 g/day (Table 2 ). In contrast, WG consumption during the RG period was 0.1 g/day on average (Table 2) . During the WG intervention, wheat was the major contributor to the increased WG intake, providing 59 % of the WG consumed, while oats, rice and corn contributed 40 % in total. Increased WG consumption was accompanied by a statistically significant increase in plasma ARs and total fibre intake, but there was no effect on other aspects of dietary intake ( Table 2) .
Effect of the WG intervention on absolute numbers of WBCs, B and T lymphocytes and NK cells and on naïve and memory T lymphocyte subsets There was no effect of the WG intervention on absolute counts of WBCs, B and T lymphocytes or NK cells (data not shown) or on naïve or memory cell subpopulations of CD4 + and CD8
+ T lymphocytes (Table 3 ). However, there was a trend towards an increase in CD4
+ Tcm cells during the WG intervention (P = 0.06). Modest positive correlations were observed between plasma ARs, but not between WG intake (Spearman's ρ, P), and absolute numbers of B (0.19, 0.03) and T (0.18, 0.05) lymphocytes and NK cells (0.23, 0.01).
Effect of the WG intervention on ex vivo phagocytic ability of monocytes and granulocytes, T cell activation and NK cell activity
The intervention had no effect on phagocytosis by monocytes or granulocytes (data not shown). There was also 0.896 no effect on the expression of CD69 by CD4 + or CD8 + T lymphocyte subsets following ex vivo stimulation of whole blood cultures (Table 4) , or on NK cell activity towards K562 cells (data not shown). ConA-stimulated expression of CD69 on CD4
+ cells tended to be higher during the RG period than the WG period (P = 0.08).
Effect of the WG intervention on serum cytokines, CRP and salivary sIgA There was no effect of the intervention on serum concentrations of cytokines or CRP (Table 5) or on salivary sIgA (data not shown). There was a trend towards a reduction in IL-10 and CRP during the WG intervention (P = 0.08 and 0.10, respectively) and a modest negative correlation between IL-1β and total fibre intake (Spearman's ρ = −0.21, P = 0.04). Despite the inverse trend with WG intake, IL-10 was positively correlated with plasma ARs (Spearman's ρ = 0.19, P = 0.04).
Effect of the WG intervention on metabolic markers
There was no effect of WG on any of the metabolic markers assessed (Table 6 ), although C-peptide, insulin and PAI-1 tended to be higher during the RG period than the WG period (P = 0.10, 0.08 and 0.07, respectively). In contrast, there was a trend towards a reduction in adipsin during the RG period compared with the WG period (P = 0.07). Adipsin was also positively correlated with plasma ARs (Spearman's ρ = 0.22, P = 0.01), but not with WG.
Discussion
This intervention resulted in a substantial increase in WG consumption in habitual low consumers of WG to an average of 168 g/day (a 500 % increase), which was associated with an increase in plasma ARs. Despite the increase in WG consumption, there were no effects on phenotypic or functional immune parameters, markers of inflammation or metabolic markers.
ARs are phenolic lipids that have been proposed as potential biomarkers of WG intake [31] and are present in the bran of rye, wheat and barley, but not in the edible parts of other cereals. In line with published data [32] , total AR concentrations were below 60 nM at baseline and during the RG arm, and the mean concentration after 6 weeks of WG intervention was 161 nmol/L. This is at the lower end of the previously reported range of 142-847 nmol/L following a WG intervention of a similar magnitude [32] .
In the current study, there were no effects of WG consumption on absolute counts of WBC, B and T lymphocytes, NK cells, naïve and memory cell subsets of CD4 + and CD8 + T lymphocytes, phagocytic ability of monocytes and granulocytes, activation (expression of CD69) of T lymphocytes after ex vivo stimulation of whole blood, activity of NK cells or concentration of saliva sIgA. While there was a trend towards increased activation of CD4 + T cells after stimulation with ConA during the RG period relative to the WG period, and a trend towards increased percentage of CD4 + Tcm cells during the WG intervention, the lack of consistent effects on immune function suggest that these are not meaningful and cannot be interpreted as either positive or negative effects.
There is currently very limited data on the impact of increased WG consumption on immune function. Single measures of immune function are notoriously difficult to interpret with respect to biological or clinical relevance, but the use of a panel of markers has the potential to identify consistent effects, which is arguably a more appropriate approach to investigating the effects of dietary components on immune function [33] . The primary immune outcomes in the current study were immune phenotyping and functional analysis, and the secondary outcomes were the circulating metabolic and inflammatory markers.
WGs, and rice, corn and wheat in particular, are important sources of phytic acid [22, 34] , a metal chelator which may enhance the activity of NK cells [23, 24] . WGs also contain arabinoxylans, β-glucans and fructans, which have structural similarities with inulin and fructooligosaccharides [25] , both of which have been shown to have beneficial effects on parameters of immune function. For example, clinical interventions in elderly adults (>65 year) demonstrate that inulin and fructooligosaccharides increase numbers of peripheral blood B cells [26] , T cells [34] , and CD4 + and CD8 + T cell subsets [35] , decrease numbers of memory CD8 + T cells [26] and improve NK cell activity [27] . However, in similar studies in young healthy individuals [35] or cancer and polypectomised patients [36] , there was little or no effect of inulin, as part of a synbiotic [36] , or of other prebiotics [35] on phagocytic activity of neutrophils [35, 36] and monocytes [36] or activity [36] and numbers of NK cells [35] .
Increased WG consumption had no effect on either serum cytokines or on CRP levels, although there were trends towards decreased IL-10 and CRP concentrations during the WG compared with the RG period. Based on epidemiological data, WG consumption has been inversely associated with inflammatory markers, and particularly CRP [37] . However, intervention studies do not always demonstrate a clear effect. Martinez et al. [13] reported reductions in IL-6 and CRP concentrations (although the latter did not reach statistical significance) after 4 weeks of consumption of 60 g/day of WG rice and barley. Katcher et al. [14] reported a 38 % reduction in CRP following a WG diet for 12 weeks. In these studies, WG products were either added to the diet instead of replacing the existing RG products [13] or subjects were given dietary advice either to avoid WG or to obtain all of their grain servings from WG [14] . Importantly, these studies were either conducted in obese volunteers with metabolic syndrome [14] or reductions in inflammatory markers were more significant in overweight subjects [13] , suggesting that health status of the subject might be a key factor determining the outcome. In another study, both a WG (60 g/day of WG) and a RG (4 g/day of WG) diet resulted in reductions between 22 and 42 % in TNF-α, IL-1β and IL-6 after 6 weeks in adolescents [38] , but some intervention studies reported no effects of WG on CRP or IL-6 after 2 [39] [16] weeks following a WG diet (between 48 and 150 g/day of WG). A number of aspects of health status may influence the impact of WG consumption on health outcomes, including the presence of metabolic syndrome or type 2 diabetes, initial concentration of the studied inflammatory markers, intervention duration, cereal type and perhaps even particular cultivar and processing. Variations in these factors may well underlie discrepancies between and within epidemiological and intervention studies. In addition, glycemic index (GI) of the foods selected for the intervention may be an important factor for consideration. A number of the WG foods provided had a medium or high GI value [41] , and GI has been demonstrated to modulate inflammatory markers [42] , perhaps even more so than WG. The desire to provide a wide range of acceptable foods to achieve a high total WG intake therefore conflicts with the potential necessity to limit the WG foods to those which are low GI, and the overall impact of WG versus GI on inflammation is not yet clear.
WG consumption had little effect on the metabolic markers examined in the current study, although there was a tendency for C-peptide, insulin and PAI-1 to decrease, while adipsin tended to increase during the WG period relative to the RG period. Reviewing observational studies and clinical trials, Koh-Banerjee and Rimm [43] concluded that WG intake is inversely associated with insulin, C-peptide and leptin concentrations. Moreover, based on epidemiological studies, PAI-1 has been related to RG and inversely associated with WG [9] . Generally, however, WG intervention studies have had mixed results in terms of markers related to glucose metabolism. Following WG interventions of 6 or 12 weeks, insulin, leptin and PAI-1 were significantly decreased in overweight or obese hyperinsulinaemic adults [20] , patients with early-stage prostate cancer [21] and obese adults with metabolic syndrome [14] , respectively. In these studies, WG was either based solely on rye [21] or consumed in a variety of products [14, 20] , similar to the current study. However, in the study of Katcher et al. [14] , total energy was restricted and the reported reduction in PAI-1 was attributed to weight loss, rather than increased consumption of WG. Indeed, loss of body weight is directly associated with lowering PAI-1 and also leptin and resistin concentrations [5] . Another study reported a decline in adiponectin levels in diabetic patients after a high-carbohydrate, low-fibre, RG wheat meal in comparison to a highcarbohydrate, high-fibre WG wheat meal [44] . On the other hand, a number of studies in healthy individuals report no effects of WG on PAI-1 [15, 16, 25] , insulin [15, 16, 18, 19] [19] or 16 [16] weeks of consuming whole meal rye bread [17] , WG wheat sourdough bread [18] , high-fibre oat or wheat cereal [19] or a variety of WG products [15, 16] , where WG intake ranged from 56 to 120 g/day [15, 16] . Notably, most studies show no effects of WG on metabolic markers in healthy subjects (n = 28-316) [15] [16] [17] [18] [19] , while clinical interventions tend to report significant effects (n = 11-60) [14, 20, 21, 44 ]. In the current study, there were no effects of the WG intervention on body weight, BMI, body fat percentage or waist circumference [29] and there was no influence of body composition on immunological parameters.
Power is an important consideration in evaluation of the evidence for health effects of WGs; inconsistency in previous data and uncertainty with respect to effect size meant that it was difficult to conduct a well-justified power calculation, and the sample size in the current study was based on interventions investigating the effect of prebiotics on phenotypic and functional immune parameters and the effect of prebiotics and WGs on the gut microbiota. The numbers of participants in previously published studies have ranged from 17 to 316, with the majority including 50 subjects or fewer. Thus, although the current study demonstrated no effects in healthy subjects, the potential for WGs to improve inflammatory markers and markers of glucose metabolism needs to be further examined, perhaps in subjects preselected for inflammatory status, and almost certainly with larger sample sizes.
Processing and the physical properties, structure and composition of the cereal grain, especially with regard to amount and type of fibre, may be important considerations in WG intervention studies. Anson et al. [45] demonstrated that bio-processing of bran in WG wheat bread resulted in increased bio-availability of phenolic acids and consumption of the processed wheat bread decreased the ratio of pro-inflammatory to anti-inflammatory cytokines in endotoxin-stimulated blood ex vivo compared with nonprocessed bread. However, evidence for effects of processing is generally limited. The role of the amount and type of fibre in WG foods is better understood, particularly with respect to carbohydrate metabolism [46] . It is well known, for example, that soluble fibre improves control of blood glucose and insulin levels [39] . Wheat contains relatively less soluble and more insoluble fibre than oats, rye or barley, which may partially explain differences in the outcomes of studies where different sources of WG were used. In the current study, 59 % of the WG intake was derived from wheat, and it was this source of WG which increased plasma ARs. It was notable that changes in some biomarkers correlated well with plasma AR concentrations, but not WG intake (e.g. adipsin), and it is tempting to speculate that this might be related to effects of wheat versus oats, rye or barley. Plasma AR concentrations may also reflect the extent of absorption of phytochemicals from WG and better represent actual exposure of the body to WG components than estimates of WG intake.
In conclusion, despite the dramatic increase in WG consumption in habitual low consumers of WG, there were no effects on phenotypic or functional immune parameters, markers of inflammation or metabolic markers. Health status of subjects, statistical power, physical and structural properties of the WGs and processing conditions may be important factors to consider in future studies.
